Clinical efficacy of JAK inhibitors for RA patients with poor-prognosis factors: the ANSWER cohort study.
We evaluated the efficacy of Janus kinase inhibitors (JAKis) compared with TNF inhibitors (TNFis) in RA patients with poor-prognosis factors (PPFs), including ACPA or RF positivity, Clinical Disease Activity Index (CDAI) ≥22, CRP ≥0.6 mg/dl and HAQ-DI Ȧ…